Literature DB >> 21154358

Quinine for muscle cramps.

Sherif El-Tawil1, Tarique Al Musa, Haseeb Valli, Michael Pt Lunn, Tariq El-Tawil, Markus Weber.   

Abstract

BACKGROUND: Muscle cramps can occur anywhere and for many reasons. Quinine has been used to treat cramps of all causes. However, controversy continues about its efficacy and safety.
OBJECTIVES: To assess the efficacy and safety of quinine in treating muscle cramps. SEARCH STRATEGY: We searched The Cochrane Neuromuscular Disease Group Register, The Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 3, 2010), MEDLINE, EMBASE and reference lists of articles up to July 2010. SELECTION CRITERIA: Randomised controlled trials of people of all ages with muscle cramps in any location and of any cause, treated with quinine or its derivatives. DATA COLLECTION AND ANALYSIS: Three authors independently selected trials for inclusion, assessed risk of bias and extracted data. We contacted study authors for additional information. MAIN
RESULTS: We identified 23 trials with a total of 1586 participants. Fifty-eight per cent of these participants were from five unpublished studies. Quinine was compared to placebo (20 trials, n =1140), vitamin E (four trials, n = 543), a quinine-vitamin E combination (three trials, n = 510), a quinine-theophylline combination (one trial, n = 77), and xylocaine injections into the gastrocnemius muscle (one trial, n = 24). The most commonly used quinine dosage was 300 mg/day (range 200 to 500 mg).Compared to placebo, quinine significantly reduced cramp number over two weeks by 28%, cramp intensity by 10%, and cramp days by 20%. Cramp duration was not significantly affected.A significantly greater number of people suffered minor adverse events on quinine than placebo (risk difference +3%, 95% confidence intervals 0% to 6%), mainly gastrointestinal symptoms. Overdoses of quinine have been reported elsewhere to cause potentially fatal adverse effects, but in the included trials there was no significant difference in major adverse events compared with placebo (risk difference 0%, 95% confidence intervals -1% to 2%). One participant suffered from thrombocytopenia (0.12% risk) on quinine.A quinine-vitamin E combination, vitamin E alone, and xylocaine injections into gastrocnemius were not significantly different to quinine across all outcomes, including adverse effects. Based on a single trial comparison, quinine alone was significantly less effective than a quinine-theophylline combination but with no significant differences in adverse events. AUTHORS'
CONCLUSIONS: There is moderate quality evidence that quinine significantly reduces cramp frequency, intensity and cramp days in dosages between 200 and 500 mg/day. There is moderate quality evidence that with use up to 60 days, the incidence of serious adverse events is not significantly greater than for placebo in the identified trials. Further research is required on the optimal dose and duration of use, and also on alternative treatments.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21154358     DOI: 10.1002/14651858.CD005044.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  16 in total

1.  Quinine: not a safe drug for treating nocturnal leg cramps.

Authors:  David B Hogan
Journal:  CMAJ       Date:  2015-01-26       Impact factor: 8.262

Review 2.  Personalizing the diuretic treatment of hypertension: the need for more clinical and research attention.

Authors:  Samuel J Mann; Michael E Ernst
Journal:  Curr Hypertens Rep       Date:  2015-04       Impact factor: 5.369

3.  Practice guidelines for pharmacists: The pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs.

Authors:  Carolyn Bornstein; Marie Craig; Diane Tin
Journal:  Can Pharm J (Ott)       Date:  2014-03

4.  Mexiletine for muscle cramps in amyotrophic lateral sclerosis: A randomized, double-blind crossover trial.

Authors:  Björn Oskarsson; Dan Moore; Tahseen Mozaffar; John Ravits; Martina Wiedau-Pazos; Nicholas Parziale; Nanette C Joyce; Ross Mandeville; Namita Goyal; Merit E Cudkowicz; Michael Weiss; Robert G Miller; Craig M McDonald
Journal:  Muscle Nerve       Date:  2018-03-06       Impact factor: 3.217

Review 5.  Magnesium for skeletal muscle cramps.

Authors:  Scott R Garrison; G Michael Allan; Ravneet K Sekhon; Vijaya M Musini; Karim M Khan
Journal:  Cochrane Database Syst Rev       Date:  2012-09-12

Review 6.  Plasmodium drug targets outside the genetic control of the parasite.

Authors:  David J Sullivan
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

Review 7.  Drug therapy for pain in amyotrophic lateral sclerosis or motor neuron disease.

Authors:  Johannes Brettschneider; Jerome Kurent; Albert Ludolph
Journal:  Cochrane Database Syst Rev       Date:  2013-06-05

Review 8.  Comprehensive rehabilitative care across the spectrum of amyotrophic lateral sclerosis.

Authors:  Sabrina Paganoni; Chafic Karam; Nanette Joyce; Richard Bedlack; Gregory T Carter
Journal:  NeuroRehabilitation       Date:  2015       Impact factor: 2.138

9.  Prevalence and morbidity associated with muscle cramps in patients with cirrhosis.

Authors:  Hemant Chatrath; Suthat Liangpunsakul; Marwan Ghabril; Julie Otte; Naga Chalasani; Raj Vuppalanchi
Journal:  Am J Med       Date:  2012-07-24       Impact factor: 4.965

10.  An Evidence-Based Review of the Pathophysiology, Treatment, and Prevention of Exercise Associated Muscle Cramps.

Authors:  Kevin C Miller; Brendon P McDermott; Susan W Yeargin; Aidan Fiol; Martin P Schwellnus
Journal:  J Athl Train       Date:  2021-06-29       Impact factor: 2.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.